Breast Cancer CDK4/6 Inhibitors in Patients with metastatic HR+/HER2-Breast Cancer

被引：0
|
作者：
Schmale, Ine
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷 / 1-2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2-Breast Cancer
    Weiss, Jennifer
    Afghahi, Anosheh
    Shagisultanova, Elena
    Diamond, Jennifer R.
    ONCOLOGY-NEW YORK, 2018, 32 (10): : 513 - 515
  • [2] Optimizing CDK4/6 inhibitors in advanced HR+/HER2-breast cancer: A personalized approach
    Fontanella, Caterina
    Giorgi, Carlo Alberto
    Russo, Stefania
    Angelini, Silvia
    Nicolardi, Linda
    Giarratano, Tommaso
    Frezzini, Simona
    Pestrin, Marta
    Palleschi, Dario
    Bolzonello, Silvia
    Parolin, Veronica
    Haspinger, Eva R.
    De Rossi, Costanza
    Greco, Filippo
    Gerratana, Lorenzo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 180
  • [3] Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer at a Single Cancer Center
    Knudsen, Erik S.
    Schultz, Emily
    Hamilton, Deanna
    Attwood, Kris
    Edge, Stephen
    O'Connor, Tracey
    Levine, Ellis
    Witkiewicz, Agnieszka K.
    ONCOLOGIST, 2022, 27 (08): : 646 - 654
  • [4] Real-world experience with CDK4/6 inhibitors for metastatic HR+/HER2-breast cancer at a single cancer center
    Milovic-Kovacevic, M.
    Bobic, S.
    Karaferic, A.
    Pavlovic, L.
    Matovic, M.
    Poparic-Bandjur, B.
    BREAST, 2023, 68 : S115 - S115
  • [5] CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer: Clinico-Pathological Analysis for Determinants of Response
    Maruthi, Vijaya Kadam
    Schultz, Emily
    Knudsen, Erik
    Witkiewicz, Agnieszka
    Hamilton, Deanna
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 136 - 138
  • [6] CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer: Clinico-Pathological Analysis for Determinants of Response
    Maruthi, Vijaya Kadam
    Schultz, Emily
    Knudsen, Erik
    Witkiewicz, Agnieszka
    Hamilton, Deanna
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 136 - 138
  • [7] Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2-breast cancer
    Wu, Sijia
    Xu, Junnan
    Ma, Yiwen
    Liang, Guilian
    Wang, Jiaxing
    Sun, Tao
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [8] Composite biomarkers for the prediction of progression-free survival with CDK4/6 inhibitors in metastatic HR+/HER2-breast cancer
    Witkiewicz, Agnieszka
    Wang, Jianxin
    Knudsen, Erik
    Levine, Ellis
    O'Connor, Tracey
    CANCER RESEARCH, 2024, 84 (09)
  • [9] HR+/HER2-metastatic Breast Cancer Increasing Data Density of CDK4/6 Inhibitors
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (09) : 485 - 485
  • [10] Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2-breast cancer: an umbrella review
    Pu, Dongqing
    Xu, Debo
    Wu, Yue
    Chen, Hanhan
    Shi, Guangxi
    Feng, Dandan
    Zhang, Mengdi
    Liu, Zhiyong
    Li, Jingwei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (01)
12345